Inflammation and the Phenomenology, Pathophysiolog Bipolar Disorder

Journal of Clinical Psychiatry 70, 1078-1090

DOI: 10.4088/jcp.08r04505

Citation Report

#	Article	IF	CITATIONS
2	TNFα –308 C→T and –863 C→A Polymorphisms and Spermiogram Characteristics. Gynecologic and Obstet Investigation, 2008, 66, 63-67.	ric 0.7	4
3	Exercise and Bipolar Disorder: A Review of Neurobiological Mediators. NeuroMolecular Medicine, 2009, 11, 328-336.	1.8	41
4	Maintenance therapy of celecoxib for major depression with mimicking neuropsychological dysfunction. General Hospital Psychiatry, 2010, 32, 647.e7-647.e9.	1,2	14
5	A psychoneuroimmunological review on cytokines involved in antidepressant treatment response. Human Psychopharmacology, 2010, 25, 201-215.	0.7	206
6	The study protocol of the Norwegian randomized controlled trial of electroconvulsive therapy in treatment resistant depression in bipolar disorder. BMC Psychiatry, 2010, 10, 16.	1.1	23
7	The Role of Adipokines in Understanding the Associations between Obesity and Depression. Journal of Obesity, 2010, 2010, 1-6.	1.1	70
8	Depression and emotional disorders in patients with physical illnesses: scientific knowledge and interventions that innovate practice. Epidemiologia E Psichiatria Sociale, 2010, 19, 95-97.	1.0	0
9	Emerging drugs for bipolar disorder. Expert Opinion on Emerging Drugs, 2010, 15, 453-466.	1.0	14
10	Brx, a link between osmotic stress, inflammation and organ physiology/pathophysiology. Expert Review of Endocrinology and Metabolism, 2010, 5, 603-614.	1.2	18
11	Aerobic Physical Exercise as a Possible Treatment for Neurocognitive Dysfunction in Bipolar Disorder. Postgraduate Medicine, 2010, 122, 107-116.	0.9	50
13	Neuroprotective effect and cognitive outcome of chronic lithium on traumatic brain injury in mice. Brain Research Bulletin, 2010, 83, 272-277.	1.4	72
14	Resilience and mental health. Clinical Psychology Review, 2010, 30, 479-495.	6.0	823
15	Falta de integridad de la sustancia blanca en la depresi \tilde{A}^3 n bipolar como posible marcador estructural de la enfermedad. Psiquiatria Biologica, 2011, 18, 79-88.	0.0	0
16	Insulin dysfunction and allostatic load in bipolar disorder. Expert Review of Neurotherapeutics, 2011, 11, 1017-1028.	1.4	54
17	Disruption of White Matter Integrity in Bipolar Depression as a Possible Structural Marker of Illness. Biological Psychiatry, 2011, 69, 309-317.	0.7	207
18	Bipolare affektive Störungen. , 2011, , 1665-1700.		0
19	Impaired nerve growth factor homeostasis in patients with bipolar disorder. World Journal of Biological Psychiatry, 2011, 12, 228-232.	1.3	55
20	Cytokine levels in the blood may distinguish suicide attempters from depressed patients. Brain, Behavior, and Immunity, 2011, 25, 335-339.	2.0	256

#	Article	IF	CITATIONS
21	Circumstantial evidence for a role of glutamine-synthetase in suicide. Medical Hypotheses, 2011, 76, 905-907.	0.8	27
22	The role of Wnt signaling and its interaction with diverse mechanisms of cellular apoptosis in the pathophysiology of bipolar disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 11-17.	2.5	18
23	Sphingolipid abnormalities in psychiatric disorders: a missing link in pathology?. Frontiers in Bioscience - Landmark, 2011, 16, 1797.	3.0	24
24	Serum levels of IL-6, IL-10 and TNF- \hat{l}_{\pm} in patients with bipolar disorder and schizophrenia: differences in pro- and anti-inflammatory balance. Revista Brasileira De Psiquiatria, 2011, 33, 268-274.	0.9	131
26	Decoding the Biology of Bipolar Disorder: An Update on Recent Findings in Genetics, Imaging, and Immunology. Focus (American Psychiatric Publishing), 2011, 9, 423-427.	0.4	1
27	Tract-specific white matter structural disruption in patients with bipolar disorder. Bipolar Disorders, 2011, 13, 414-424.	1.1	122
28	Peripheral biomarkers and illness activity in bipolar disorder. Journal of Psychiatric Research, 2011, 45, 156-161.	1.5	208
29	Systemic toxicity in early-stage mood disorders. Journal of Psychiatric Research, 2011, 45, 1407-1409.	1.5	16
30	Affective symptoms are associated with markers of inflammation and immune activation in bipolar disorders but not in schizophrenia. Journal of Psychiatric Research, 2011, 45, 1608-1616.	1.5	146
31	Screening for bipolar disorder in patients consulting general practitioners in France. Journal of Affective Disorders, 2011, 130, 492-495.	2.0	19
32	Genetic association between bipolar disorder and 524A>C (Leu133Ile) polymorphism of CNR2 gene, encoding for CB2 cannabinoid receptor. Journal of Affective Disorders, 2011, 134, 427-430.	2.0	58
33	Recent advances in psychoneuroimmunology: Inflammation in psychiatric disorders. Translational Neuroscience, 2011, 2, .	0.7	18
34	Increased plasma levels of soluble TNF receptor I in patients with bipolar disorder. European Archives of Psychiatry and Clinical Neuroscience, 2011, 261, 139-143.	1.8	93
35	Surgical treatment of morbid obesity among patients with bipolar disorder: a research agenda. Advances in Therapy, 2011, 28, 389-400.	1.3	13
36	Pathways underlying neuroprogression in bipolar disorder: Focus on inflammation, oxidative stress and neurotrophic factors. Neuroscience and Biobehavioral Reviews, 2011, 35, 804-817.	2.9	1,007
37	Preliminary Findings Regarding Proinflammatory Markers and Brain-Derived Neurotrophic Factor Among Adolescents with Bipolar Spectrum Disorders. Journal of Child and Adolescent Psychopharmacology, 2011, 21, 479-484.	0.7	88
38	Depressive Symptoms in a General Population: Associations with Obesity, Inflammation, and Blood Pressure. Cardiology Research and Practice, 2011, 2011, 1-7.	0.5	7
39	Elevation of cerebrospinal fluid interleukin- $\hat{\Pi}^2$ in bipolar disorder. Journal of Psychiatry and Neuroscience, 2011, 36, 114-118.	1.4	151

#	ARTICLE	IF	Citations
40	Up-Regulation of <i>NOTCH4</i> Gene Expression in Bipolar Disorder. American Journal of Psychiatry, 2012, 169, 1292-1300.	4.0	44
41	A multi-tissue analysis identifies HLA complex group 9 gene methylation differences in bipolar disorder. Molecular Psychiatry, 2012, 17, 728-740.	4.1	117
42	The Risk Factors for Elderly Patients With Bipolar Disorder Having Cerebral Infarction. Journal of Geriatric Psychiatry and Neurology, 2012, 25, 15-19.	1.2	17
43	Metabolic Syndrome and Bipolar Disorder: What Should Psychiatrists Know?. CNS Neuroscience and Therapeutics, 2012, 18, 160-166.	1.9	44
44	Effects of lithium on lipopolysaccharide-induced inflammation in rat primary glia cells. Innate Immunity, 2012, 18, 447-458.	1.1	62
45	Markers of gluten sensitivity in acute mania: A longitudinal study. Psychiatry Research, 2012, 196, 68-71.	1.7	41
46	Inflammatory cytokines as an underlying mechanism of the comorbidity between bipolar disorder and migraine. Medical Hypotheses, 2012, 78, 601-605.	0.8	24
47	Design and rationale of a randomized controlled trial to reduce cardiovascular disease risk for patients with bipolar disorder. Contemporary Clinical Trials, 2012, 33, 666-678.	0.8	17
48	Stateâ€related alterations of gene expression in bipolar disorder: a systematic review. Bipolar Disorders, 2012, 14, 684-696.	1.1	38
49	Selected Cytokine Profiles during Remission in Bipolar Patients. Neuropsychobiology, 2012, 66, 193-198.	0.9	37
50	Cognitive impairment is related to oxidative stress and chemokine levels in first psychotic episodes. Schizophrenia Research, 2012, 137, 66-72.	1.1	96
51	Cardiovascular risk factors during second generation antipsychotic treatment are associated with increased C-reactive protein. Schizophrenia Research, 2012, 140, 169-174.	1.1	38
52	Obesity in Bipolar Disorder: An Overview. Current Psychiatry Reports, 2012, 14, 650-658.	2.1	103
53	Can bipolar disorder be viewed as a multi-system inflammatory disease?. Journal of Affective Disorders, 2012, 141, 1-10.	2.0	369
54	Elevated immune-inflammatory signaling in mood disorders: a new therapeutic target?. Expert Review of Neurotherapeutics, 2012, 12, 1143-1161.	1.4	92
55	Plasma concentrations of soluble cytokine receptors in euthymic bipolar patients with and without subsyndromal symptoms. BMC Psychiatry, 2012, 12, 158.	1.1	24
56	Reconsidering the Association Between the Major Histocompatibility Complex and Bipolar Disorder. Journal of Molecular Neuroscience, 2012, 47, 26-30.	1.1	21
57	Inflammatory markers and their relationships with leptin and insulin from acute mania to full remission in bipolar disorder. Journal of Affective Disorders, 2012, 136, 110-116.	2.0	91

#	Article	IF	CITATIONS
58	Executive dysfunction in euthymic bipolar disorder patients and its association with plasma biomarkers. Journal of Affective Disorders, 2012, 137, 151-155.	2.0	97
59	Mood disorder symptoms and elevated cardiovascular disease risk in patients with bipolar disorder. Journal of Affective Disorders, 2012, 138, 405-408.	2.0	32
60	Increased levels of adipokines in bipolar disorder. Journal of Psychiatric Research, 2012, 46, 389-393.	1.5	72
61	Mitochondria, oligodendrocytes and inflammation in bipolar disorder: Evidence from transcriptome studies points to intriguing parallels with multiple sclerosis. Neurobiology of Disease, 2012, 45, 37-47.	2.1	130
62	Mediators of allostasis and systemic toxicity in bipolar disorder. Physiology and Behavior, 2012, 106, 46-50.	1.0	100
63	Recognition of bipolar disorder type I before the first manic episode: challenges and developments. Expert Review of Neurotherapeutics, 2013, 13, 795-807.	1.4	11
64	Cytokines in bipolar disorder vs. healthy control subjects: A systematic review and meta-analysis. Journal of Psychiatric Research, 2013, 47, 1119-1133.	1.5	358
65	Melancholic and atypical major depression â€" Connection between cytokines, psychopathology and treatment. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 43, 1-6.	2.5	71
66	The Presentation, Recognition and Management of Bipolar Depression in Primary Care. Journal of General Internal Medicine, 2013, 28, 1648-1656.	1.3	17
67	Chemokines in bipolar disorder: Trait or state?. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 159-165.	1.8	78
68	Differential neuroendocrine and immune responses to acute psychosocial stress in women with type 1 bipolar disorder. Brain, Behavior, and Immunity, 2013, 34, 47-55.	2.0	49
69	Neurotrophins, inflammation and oxidative stress as illness activity biomarkers in bipolar disorder. Expert Review of Neurotherapeutics, 2013, 13, 827-842.	1.4	57
70	Inflammation and neurological disease-related genes are differentially expressed in depressed patients with mood disorders and correlate with morphometric and functional imaging abnormalities. Brain, Behavior, and Immunity, 2013, 31, 161-171.	2.0	127
71	Posttraumatic stress disorder, depression, and health-related quality of life in patients with bipolar disorder: Review and new data from a multi-site community clinic sample. Journal of Affective Disorders, 2013, 145, 232-239.	2.0	23
72	Altered intracellular signaling cascades in peripheral blood mononuclear cells from BD patients. Journal of Psychiatric Research, 2013, 47, 1949-1954.	1.5	37
73	The Link between High-Sensitivity C-Reactive Protein and Orbitofrontal Cortex in Euthymic Bipolar Disorder. Neuropsychobiology, 2013, 68, 168-173.	0.9	31
74	Clinical phenotype of bipolar disorder with comorbid binge eating disorder. Journal of Affective Disorders, 2013, 150, 981-986.	2.0	56
75	The effect of bariatric surgery on psychiatric course among patients with bipolar disorder. Bipolar Disorders, 2013, 15, 753-763.	1.1	35

#	ARTICLE	IF	Citations
76	Cytokines in bipolar disorder: A systematic review and meta-analysis. Journal of Affective Disorders, 2013, 144, 16-27.	2.0	229
77	Immunity, Inflammation, and Bipolar Disorder: Diagnostic and Therapeutic Implications. Current Psychiatry Reports, 2013, 15, 387.	2.1	83
78	Toward Clinically Applicable Biomarkers in Bipolar Disorder: Focus on BDNF, Inflammatory Markers, and Endothelial Function. Current Psychiatry Reports, 2013, 15, 425.	2.1	66
79	The role of the innate immune system in psychiatric disorders. Molecular and Cellular Neurosciences, 2013, 53, 52-62.	1.0	226
80	Interleukin 1 receptor antagonist and soluble tumor necrosis factor receptor 1 are associated with general severity and psychotic symptoms in schizophrenia and bipolar disorder. Schizophrenia Research, 2013, 145, 36-42.	1.1	118
81	Staging and Neuroprogression in Bipolar Disorder: A Systematic Review of the Literature. Revista Brasileira De Psiquiatria, 2013, 35, 70-74.	0.9	97
82	Not All Inflammatory Biomarkers Are Elevated in Bipolar Disorder: Evidence for Procalcitonin. Biological Psychiatry, 2013, 74, e29-e30.	0.7	8
83	C-reactive protein as a marker of cardiovascular disease in patients with a schizophrenia spectrum disorder treated in routine medical practice. European Psychiatry, 2013, 28, 161-167.	0.1	26
84	Interleukin- $1\hat{l}^2$ is associated with depressive episode in major depression but not in bipolar disorder. Journal of Psychiatric Research, 2013, 47, 2011-2014.	1.5	45
85	Bipolar Disorder and Metabolic Syndrome: A Systematic Review. Revista Brasileira De Psiquiatria, 2013, 35, 88-93.	0.9	65
86	Hiking in Suicidal Patients: Neutral Effects on Markers of Suicidality. American Journal of Medicine, 2013, 126, 927-930.	0.6	13
87	The HLA-G low expressor genotype is associated with protection against bipolar disorder. Human Immunology, 2013, 74, 593-597.	1.2	30
88	Relationship between Toxoplasma gondii infection and bipolar disorder in a French sample. Journal of Affective Disorders, 2013, 148, 444-448.	2.0	102
89	Acute manic episode is associated with an increased risk of lower limb edema. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 47, 99-103.	2.5	4
90	Reduced regulatory T cells are associated with higher levels of Th1/TH17 cytokines and activated MAPK in type 1 bipolar disorder. Psychoneuroendocrinology, 2013, 38, 667-676.	1.3	103
91	Is there a role for curcumin in the treatment of bipolar disorder?. Medical Hypotheses, 2013, 80, 606-612.	0.8	20
92	Altered chemokine levels in the cerebrospinal fluid and plasma of suicide attempters. Psychoneuroendocrinology, 2013, 38, 853-862.	1.3	53
93	Cytokine Alterations in Bipolar Disorder: A Meta-Analysis of 30 Studies. Biological Psychiatry, 2013, 74, 15-25.	0.7	504

#	Article	IF	CITATIONS
94	White matter differences in euthymic bipolar I disorder: a combined magnetic resonance imaging and diffusion tensor imaging voxelâ€based study. Bipolar Disorders, 2013, 15, 365-376.	1.1	50
95	The Clinical Implications Of Cognitive Impairment and Allostatic Load in Bipolar Disorder. European Psychiatry, 2013, 28, 21-29.	0.1	119
96	The shared role of oxidative stress and inflammation in major depressive disorder and nicotine dependence. Neuroscience and Biobehavioral Reviews, 2013, 37, 1336-1345.	2.9	73
97	Cardiovascular mortality in bipolar disorder: a population-based cohort study in Sweden. BMJ Open, 2013, 3, e002373.	0.8	154
98	Inflammation, Neurotoxins and Psychiatric Disorders. Modern Problems of Pharmacopsychiatry, 2013, 28, 61-74.	2.5	16
99	Is bipolar disorder an inflammatory condition? The relevance of microglial activation. Current Opinion in Psychiatry, 2013, 26, 19-26.	3.1	160
100	Influence of IL-1RN Intron 2 Variable Number of Tandem Repeats (VNTR) Polymorphism on Bipolar Disorder. Neuropsychobiology, 2013, 67, 116-121.	0.9	12
101	The association between immune activation and manic symptoms in patients with a depressive disorder. Translational Psychiatry, 2013, 3, e314-e314.	2.4	60
102	Inflammation Theories in Psychotic Disorders: A Critical Review. Infectious Disorders - Drug Targets, 2013, 13, 59-70.	0.4	54
103	Collagen XVII: A Shared Antigen in Neurodermatological Interactions?. Clinical and Developmental Immunology, 2013, 2013, 1-7.	3.3	35
104	Gastroesophageal Reflux Disease and Risk for Bipolar Disorder: A Nationwide Population-Based Study. PLoS ONE, 2014, 9, e107694.	1.1	12
105	Stress, Inflammation, and Cellular Vulnerability during Early Stages of Affective Disorders: Biomarker Strategies and Opportunities for Prevention and Intervention. Frontiers in Psychiatry, 2014, 5, 34.	1.3	48
106	Biomarkers for drugs of abuse and neuropsychiatric disorders. , 2014, , 983-1001.		4
107	The KMO allele encoding Arg452 is associated with psychotic features in bipolar disorder type 1, and with increased CSF KYNA level and reduced KMO expression. Molecular Psychiatry, 2014, 19, 334-341.	4.1	91
108	Leptin Is Associated with Mood Status and Metabolic Homeostasis in Patients with Bipolar Disorder. Neuropsychobiology, 2014, 70, 203-209.	0.9	14
109	Integrated Neurobiology of Bipolar Disorder. Frontiers in Psychiatry, 2014, 5, 98.	1.3	160
110	The neurobiology of bipolar disorder: identifying targets for specific agents and synergies for combination treatment. International Journal of Neuropsychopharmacology, 2014, 17, 1039-1052.	1.0	58
111	Therapeutic effects of add-on low-dose dextromethorphan plus valproic acid in bipolar disorder. European Neuropsychopharmacology, 2014, 24, 1753-1759.	0.3	29

#	Article	IF	CITATIONS
112	The Importance of Clia in Dealing with Stress. Psychiatric Clinics of North America, 2014, 37, 679-705.	0.7	4
113	Effectiveness and tolerance of antiâ€inflammatory drugs' addâ€on therapy in major mental disorders: a systematic qualitative review. Acta Psychiatrica Scandinavica, 2014, 129, 163-179.	2.2	140
114	The Effects of Add-On Low-Dose Memantine on Cytokine Levels in Bipolar II Depression. Journal of Clinical Psychopharmacology, 2014, 34, 337-343.	0.7	39
115	Persistent inflammation and its relationship to leptin and insulin in phases of bipolar disorder from acute depression to full remission. Bipolar Disorders, 2014, 16, 800-808.	1.1	32
116	Regulation of GSK-3 Activity as A Shared Mechanism in Psychiatric Disorders. Journal of Microbiology and Biotechnology, 2014, 24, 97-108.	0.9	6
117	The relationship between neurotrophins and bipolar disorder. Expert Review of Neurotherapeutics, 2014, 14, 51-65.	1.4	23
118	Association between bipolar episodes and fluid and electrolyte homeostasis: a retrospective longitudinal study. Bipolar Disorders, 2014, 16, 781-789.	1.1	11
119	Interventions for Youth at Risk of Bipolar Disorder. Current Treatment Options in Psychiatry, 2014, 1, 37-47.	0.7	6
120	The theory of bipolar disorder as an illness of accelerated aging: Implications for clinical care and research. Neuroscience and Biobehavioral Reviews, 2014, 42, 157-169.	2.9	146
121	Chemokines and chemokine receptors in mood disorders, schizophrenia, and cognitive impairment: A systematic review of biomarker studies. Neuroscience and Biobehavioral Reviews, 2014, 42, 93-115.	2.9	212
122	Association of thalamic serotonin transporter and interleukinâ€10 in bipolar I disorder: a <scp>SPECT</scp> study. Bipolar Disorders, 2014, 16, 241-248.	1.1	24
123	Polymorphism of Toll-like receptor 4 gene in bipolar disorder. Journal of Affective Disorders, 2014, 152-154, 395-402.	2.0	53
124	Seroreactive marker for inflammatory bowel disease and associations with antibodies to dietary proteins in bipolar disorder. Bipolar Disorders, 2014, 16, 230-240.	1.1	61
125	Inflamed moods: A review of the interactions between inflammation and mood disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 53, 23-34.	2.5	468
126	Autoimmunity, Inflammation, and Psychosis: A Search for Peripheral Markers. Biological Psychiatry, 2014, 75, 324-331.	0.7	224
127	Inflammation and the two-hit hypothesis of schizophrenia. Neuroscience and Biobehavioral Reviews, 2014, 38, 72-93.	2.9	218
128	The relationship between interleukinâ€1 receptor antagonist and cognitive function in older adults with bipolar disorder. International Journal of Geriatric Psychiatry, 2014, 29, 635-644.	1.3	70
129	Biomarkers and clinical staging in psychiatry. World Psychiatry, 2014, 13, 211-223.	4.8	243

#	Article	IF	CITATIONS
130	Role of immunological factors in the pathophysiology and diagnosis of bipolar disorder: Comparison with schizophrenia. Psychiatry and Clinical Neurosciences, 2014, 68, 21-36.	1.0	80
131	Association of asthma and bipolar disorder: A nationwide population-based study in Taiwan. Journal of Affective Disorders, 2014, 168, 30-36.	2.0	18
132	Common biological mechanisms between bipolar disorder and type 2 diabetes: Focus on inflammation. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 54, 289-298.	2.5	28
133	Lithium and the Other Mood Stabilizers Effective in Bipolar Disorder Target the Rat Brain Arachidonic Acid Cascade. ACS Chemical Neuroscience, 2014, 5, 459-467.	1.7	66
134	Pro-inflammatory cytokines and soluble receptors in response to acute psychosocial stress: Differential reactivity in bipolar disorder. Neuroscience Letters, 2014, 580, 17-21.	1.0	20
135	Glia and immune cell signaling in bipolar disorder: insights from neuropharmacology and molecular imaging to clinical application. Translational Psychiatry, 2014, 4, e350-e350.	2.4	80
136	Inflammatory biomarker profiles of mental disorders and their relation to clinical, social and lifestyle factors. Social Psychiatry and Psychiatric Epidemiology, 2014, 49, 841-849.	1.6	125
137	Inflammation in Children and Adolescents With Neuropsychiatric Disorders: A SystematicÂReview. Journal of the American Academy of Child and Adolescent Psychiatry, 2014, 53, 274-296.	0.3	202
138	Reduced Serum Adiponectin Levels in Alexithymia. NeuroImmunoModulation, 2014, 21, 234-239.	0.9	5
139	Proteomics and Metabolomics of Bipolar Disorder. Advances in Biological Psychiatry, 2014, , 116-116.	0.2	2
140	The expression of cytokines and chemokines in the blood of patients with severe weight loss from anorexia nervosa: An exploratory study. Cytokine, 2014, 69, 110-115.	1.4	23
141	Effects of Lithium on Inflammation. ACS Chemical Neuroscience, 2014, 5, 451-458.	1.7	157
142	The Impact of Soluble Interleukin-2 Receptor as a Biomarker of Delirium. Psychosomatics, 2014, 55, 51-60.	2.5	6
143	Comparison of inflammatory cytokine levels among type I/type II and manic/hypomanic/euthymic/depressive states of bipolar disorder. Journal of Affective Disorders, 2014, 166, 187-192.	2.0	98
144	Anxiety, not anger, induces inflammatory activity: An avoidance/approach model of immune system activation Emotion, 2015, 15, 463-476.	1.5	43
145	Lithium modulates the production of peripheral and cerebral cytokines in an animal model of mania induced by dextroamphetamine. Bipolar Disorders, 2015, 17, 507-517.	1.1	46
146	Pentraxin 3 is reduced in bipolar disorder. Bipolar Disorders, 2015, 17, 409-414.	1.1	16
147	Association between history of psychosis and cardiovascular disease in bipolar disorder. Bipolar Disorders, 2015, 17, 518-527.	1.1	12

#	Article	IF	Citations
148	Immune alterations in acute bipolar depression. Acta Psychiatrica Scandinavica, 2015, 132, 204-210.	2.2	27
149	Discrimination between Alzheimer's Disease and Late Onset Bipolar Disorder Using Multivariate Analysis. Frontiers in Aging Neuroscience, 2015, 7, 231.	1.7	28
150	Kynurenine 3-Monooxygenase: An Influential Mediator of Neuropathology. Frontiers in Psychiatry, 2015, 6, 116.	1.3	105
151	Biomarkers and staging of bipolar disorder: a systematic review. Trends in Psychiatry and Psychotherapy, 2015, 37, 03-11.	0.4	35
152	Specific alterations in plasma proteins during depressed, manic, and euthymic states of bipolar disorder. Brazilian Journal of Medical and Biological Research, 2015, 48, 973-982.	0.7	37
153	A Review of Biomarkers in Mood and Psychotic Disorders: A Dissection of Clinical vs. Preclinical Correlates. Current Neuropharmacology, 2015, 13, 324-368.	1.4	75
154	Disruption in the Blood-Brain Barrier: The Missing Link between Brain and Body Inflammation in Bipolar Disorder?. Neural Plasticity, 2015, 2015, 1-12.	1.0	139
155	Monocyte and microglial activation in patients with mood-stabilized bipolar disorder. Journal of Psychiatry and Neuroscience, 2015, 40, 250-258.	1.4	75
156	Beyond Monoamines-Novel Targets for Treatment-Resistant Depression: A Comprehensive Review. Current Neuropharmacology, 2015, 13, 636-655.	1.4	50
157	The genetics of early-onset bipolar disorder: A systematic review. Journal of Affective Disorders, 2015, 184, 1-12.	2.0	31
158	Serum levels of carcinoembryonic antigen (CEA) in patients with bipolar disorder. Acta Neuropsychiatrica, 2015, 27, 177-181.	1.0	4
159	CSF neuroinflammatory biomarkers in bipolar disorder are associated with cognitive impairment. European Neuropsychopharmacology, 2015, 25, 1091-1098.	0.3	47
160	Levels of C-reactive protein (CRP) in patients with schizophrenia, unipolar depression and bipolar disorder. Nordic Journal of Psychiatry, 2015, 69, 346-353.	0.7	72
161	Premorbid obesity and metabolic disturbances as promising clinical targets for the prevention and early screening of bipolar disorder. Medical Hypotheses, 2015, 84, 285-293.	0.8	12
162	Genetic pleiotropy between multiple sclerosis and schizophrenia but not bipolar disorder: differential involvement of immune-related gene loci. Molecular Psychiatry, 2015, 20, 207-214.	4.1	173
163	Novel investigational drugs targeting IL-6 signaling for the treatment of depression. Expert Opinion on Investigational Drugs, 2015, 24, 459-475.	1.9	41
164	The role of genetic variation across IL- \hat{l}^2 , IL-2, IL-6, and BDNF in antipsychotic-induced weight gain. World Journal of Biological Psychiatry, 2015, 16, 45-56.	1.3	28
165	Five Youth with Pediatric Acute-Onset Neuropsychiatric Syndrome of Differing Etiologies. Journal of Child and Adolescent Psychopharmacology, 2015, 25, 31-37.	0.7	41

#	ARTICLE	IF	CITATIONS
166	Reduced mRNA Expression of PTGDS in Peripheral Blood Mononuclear Cells of Rapid-Cycling Bipolar Disorder Patients Compared with Healthy Control Subjects. International Journal of Neuropsychopharmacology, 2015, 18, pyu101-pyu101.	1.0	22
167	Antibody Profiling of Bipolar Disorder Using Escherichia coli Proteome Microarrays. Molecular and Cellular Proteomics, 2015, 14, 510-518.	2.5	10
168	Staging bipolar disorder: what data and what models are needed?. Lancet Psychiatry,the, 2015, 2, 564-570.	3.7	29
169	Molecular effects of lithium are partially mimicked by inositol-monophosphatase (IMPA)1 knockout mice in a brain region-dependent manner. European Neuropsychopharmacology, 2015, 25, 425-434.	0.3	23
170	Oxidative markers of Myeloperoxidase and Catalase and their diagnostic performance in bipolar disorder. Journal of Affective Disorders, 2015, 181, 92-95.	2.0	26
171	Causes of decreased life expectancy over the life span in bipolar disorder. Journal of Affective Disorders, 2015, 180, 142-147.	2.0	139
172	Enrichment pathway analysis. The inflammatory genetic background in Bipolar Disorder. Journal of Affective Disorders, 2015, 179, 88-94.	2.0	44
173	Trans-fat supplementation over two generations of rats exacerbates behavioral and biochemical damages in a model of mania: Co-treatment with lithium. Life Sciences, 2015, 132, 6-12.	2.0	6
174	Increased risk of hyperlipidemia in patients with bipolar disorder: a population-based study. General Hospital Psychiatry, 2015, 37, 294-298.	1.2	37
175	Are medical comorbid conditions of bipolar disorder due to immune dysfunction?. Acta Psychiatrica Scandinavica, 2015, 132, 180-191.	2.2	84
176	Cognitive deterioration among bipolar disorder patients infected by Toxoplasma gondii is correlated to interleukin 6 levels. Journal of Affective Disorders, 2015, 179, 161-166.	2.0	49
177	Obesity and Chronic Pain. Regional Anesthesia and Pain Medicine, 2015, 40, 91-111.	1.1	93
178	Life expectancy in bipolar disorder. Bipolar Disorders, 2015, 17, 543-548.	1.1	142
179	Resolution of a manic episode treated with activated charcoal: Evidence for a brain–gut axis in bipolar disorder. Australian and New Zealand Journal of Psychiatry, 2015, 49, 1221-1223.	1.3	18
180	Increased Cerebral Blood Flow Associated with Better Response Inhibition in Bipolar Disorder. Journal of the International Neuropsychological Society, 2015, 21, 105-115.	1.2	19
181	Dysregulation of the NF-κB pathway as a potential inducer of bipolar disorder. Journal of Psychiatric Research, 2015, 70, 18-27.	1.5	31
182	Mitigation of Inflammation-Induced Mood Dysregulation by Long-Chain Omega-3 Fatty Acids. Journal of the American College of Nutrition, 2015, 34, 48-55.	1.1	20
183	Inflammation as a neurobiological substrate of cognitive impairment in bipolar disorder: Evidence, pathophysiology and treatment implications. Journal of Affective Disorders, 2015, 188, 149-159.	2.0	126

#	Article	IF	CITATIONS
184	Evidence to support peripheral and central IL-6 signaling targets to treat depression. Expert Opinion on Investigational Drugs, 2015, 24, 991-992.	1.9	1
185	Major Depressive Disorder and Bipolar Disorder Predispose Youth to Accelerated Atherosclerosis and Early Cardiovascular Disease. Circulation, 2015, 132, 965-986.	1.6	371
186	Brainâ€derived neurotrophic factor and inflammatory markers in schoolâ€eged children with early trauma. Acta Psychiatrica Scandinavica, 2015, 131, 360-368.	2.2	41
187	Taking the fuel out of the fire: Evidence for the use of anti-inflammatory agents in the treatment of bipolar disorders. Journal of Affective Disorders, 2015, 174, 467-478.	2.0	48
188	Increased cerebrospinal fluid interleukin-8 in bipolar disorder patients associated with lithium and antipsychotic treatment. Brain, Behavior, and Immunity, 2015, 43, 198-204.	2.0	51
189	The "psychomicrobiotic― Targeting microbiota in major psychiatric disorders: A systematic review. Pathologie Et Biologie, 2015, 63, 35-42.	2.2	158
190	Multi-level biomarker analysis of nitric oxide synthase isoforms in bipolar disorder and adult ADHD. Journal of Psychopharmacology, 2015, 29, 31-38.	2.0	28
191	Association between altered brain morphology and elevated peripheral endothelial markers — Implications for psychotic disorders. Schizophrenia Research, 2015, 161, 222-228.	1.1	23
192	Monocyte activation, brainâ€derived neurotrophic factor (<scp>BDNF</scp>), and S100B in bipolar offspring: a followâ€up study from adolescence into adulthood. Bipolar Disorders, 2015, 17, 39-49.	1.1	40
193	Elevated levels of IL-6 and IL-18 in manic and hypomanic states in rapid cycling bipolar disorder patients. Brain, Behavior, and Immunity, 2015, 43, 205-213.	2.0	7 3
194	The influence of inflammatory cytokines in physiopathology of suicidal behavior. Journal of Affective Disorders, 2015, 172, 219-230.	2.0	47
195	Soluble Urokinase-Type Plasminogen Activator Receptor Levels in Patients With Schizophrenia. Schizophrenia Bulletin, 2015, 41, 764-771.	2.3	16
196	General medical conditions in 347 bipolar disorder patients: Clinical correlates of metabolic and autoimmune-allergic diseases. Journal of Affective Disorders, 2015, 170, 95-103.	2.0	74
197	The Adverse Effects of Smoking on Health Outcomes in Bipolar Disorder: A Review and Synthesis of Biological Mechanisms. Current Molecular Medicine, 2016, 16, 187-205.	0.6	13
198	Staging Models in Bipolar Disorder: A Systematic Review of the Literature. Clinical Psychopharmacology and Neuroscience, 2016, 14, 117-130.	0.9	59
199	Bipolar Disorder: Role of Inflammation and the Development of Disease Biomarkers. Psychiatry Investigation, 2016, 13, 18.	0.7	136
200	Minocycline and celecoxib as adjunctive treatments for bipolar depression: a study protocol for a multicenter factorial design randomized controlled trial. Neuropsychiatric Disease and Treatment, 2017, Volume 13, 1-8.	1.0	23
201	A new look at an old drug: neuroprotective effects and therapeutic potentials of lithium salts. Neuropsychiatric Disease and Treatment, 2016, Volume 12, 1687-1703.	1.0	64

#	Article	IF	CITATIONS
202	Pharmacologic implications of inflammatory comorbidity in bipolar disorder. Current Opinion in Pharmacology, 2016, 29, 63-69.	1.7	21
203	Metaâ€analysis of erythrocyte polyunsaturated fatty acid biostatus in bipolar disorder. Bipolar Disorders, 2016, 18, 300-306.	1.1	49
204	C-reactive protein in bipolar disorder. Lancet Psychiatry, the, 2016, 3, 1096-1098.	3.7	3
205	Does CRP predict outcome in bipolar disorder in regular outpatient care?. International Journal of Bipolar Disorders, 2016, 4, 14.	0.8	10
206	Increasing US health plan coverage for exercise programming in community mental health settings for people with serious mental illness: a position statement from the Society of Behavior Medicine and the American College of Sports Medicine. Translational Behavioral Medicine, 2016, 6, 478-481.	1.2	30
207	Risk of bipolar disorder in patients with COPD: a population-based cohort study. General Hospital Psychiatry, 2016, 41, 6-12.	1.2	9
208	Associations between comorbid health conditions and the use of mental health services among adults with bipolar disorder. Social Work in Health Care, 2016, 55, 28-40.	0.8	4
209	Migraine headache and bipolar disorder comorbidity: A systematic review of the literature and clinical implications. Scandinavian Journal of Pain, 2016, 11, 136-145.	0.5	39
210	Low vitamin D is associated with negative and depressive symptoms in psychotic disorders. Schizophrenia Research, 2016, 178, 44-49.	1.1	29
211	Natural Withanolides in the Treatment of Chronic Diseases. Advances in Experimental Medicine and Biology, 2016, 928, 329-373.	0.8	64
212	Altered serum levels of TNF-α, IL-6 and IL-18 in manic, depressive, mixed state of bipolar disorder patients. Psychiatry Research, 2016, 244, 19-23.	1.7	57
213	Increased risk of chronic liver disease in patients with bipolar disorder: A population-based study. General Hospital Psychiatry, 2016, 42, 54-59.	1.2	22
214	Bipolar disorder and diabetes mellitus: evidence for disease-modifying effects and treatment implications. International Journal of Bipolar Disorders, 2016, 4, 13.	0.8	41
215	Comparing clinical responses and the biomarkers of BDNF and cytokines between subthreshold bipolar disorder and bipolar II disorder. Scientific Reports, 2016, 6, 27431.	1.6	15
216	Physical health and metabolic dysfunction in bipolar disorder., 2016,, 256-268.		0
217	The effect of mood-stabilizing drugs on cytokine levels in bipolar disorder: A systematic review. Journal of Affective Disorders, 2016, 203, 364-373.	2.0	58
218	Levels of C-reactive protein (CRP) in elderly patients with unipolar depression – case control analysis. Nordic Journal of Psychiatry, 2016, 70, 503-507.	0.7	4
219	Association between the serotonin transporter and cytokines: Implications for the pathophysiology of bipolar disorder. Journal of Affective Disorders, 2016, 191, 29-35.	2.0	21

#	Article	IF	Citations
221	Modulatory effects of $\hat{l}\pm7$ nAChRs on the immune system and its relevance for CNS disorders. Cellular and Molecular Life Sciences, 2016, 73, 2511-2530.	2.4	135
222	Risk of psychiatric disorders following pelvic inflammatory disease: a nationwide population-based retrospective cohort study. Journal of Psychosomatic Obstetrics and Gynaecology, 2016, 37, 6-11.	1.1	12
223	The Differential Levels of Inflammatory Cytokines and BDNF among Bipolar Spectrum Disorders. International Journal of Neuropsychopharmacology, 2016, 19, pyw012.	1.0	30
224	Mapping inflammation onto mood: Inflammatory mediators of anhedonia. Neuroscience and Biobehavioral Reviews, 2016, 64, 148-166.	2.9	97
226	Relationship between body mass index and hippocampal glutamate/glutamine in bipolar disorder. British Journal of Psychiatry, 2016, 208, 146-152.	1.7	16
227	Childhood maltreatment and unfavourable clinical outcomes in bipolar disorder: a systematic review and meta-analysis. Lancet Psychiatry,the, 2016, 3, 342-349.	3.7	293
228	Bipolar Disorder and Inflammation. Psychiatric Clinics of North America, 2016, 39, 125-137.	0.7	125
229	Elevated C-reactive protein and late-onset bipolar disorder in 78 809 individuals from the general population. British Journal of Psychiatry, 2016, 208, 138-145.	1.7	52
230	Inflammatory evidence for the psychosis continuum model. Psychoneuroendocrinology, 2016, 67, 189-197.	1.3	39
231	Candidate Risks Indicators for Bipolar Disorder: Early Intervention Opportunities in High-Risk Youth. International Journal of Neuropsychopharmacology, 2016, 19, pyv071.	1.0	45
232	Abdominal obesity is associated with impaired cognitive function in euthymic bipolar individuals. World Journal of Biological Psychiatry, 2016, 17, 535-546.	1.3	51
233	Refractory bipolar disorder and neuroprogression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 70, 103-110.	2.5	35
234	Immune and Neuroendocrine Mechanisms of Stress Vulnerability and Resilience. Neuropsychopharmacology, 2017, 42, 62-80.	2.8	241
235	Cognitive Impairment and Older Age Bipolar Disorder. , 2017, , 107-126.		2
236	Increased ratio of high sensitivity C-reactive protein to interleukin-10 as a potential peripheral biomarker of schizophrenia and aggression. International Journal of Psychophysiology, 2017, 114, 9-15.	0.5	24
237	Emotional reactivity, functioning, and C-reactive protein alterations in remitted bipolar patients: Clinical relevance of a dimensional approach. Australian and New Zealand Journal of Psychiatry, 2017, 51, 788-798.	1.3	15
238	Shared metabolic and immune-inflammatory, oxidative and nitrosative stress pathways in the metabolic syndrome and mood disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 78, 34-50.	2.5	126
239	Precursors in adolescence of adult-onset bipolar disorder. Journal of Affective Disorders, 2017, 218, 353-358.	2.0	9

#	Article	IF	CITATIONS
240	Effect of memantine on C-reactive protein and lipid profiles in bipolar disorder. Journal of Affective Disorders, 2017, 221, 151-157.	2.0	1
241	Increased risk of chronic obstructive pulmonary disease in patients with bipolar disorder: A population-based study. Journal of Affective Disorders, 2017, 220, 43-48.	2.0	15
242	Structural and functional correlates of serum soluble IL-6 receptor level in patients with bipolar disorder. Journal of Affective Disorders, 2017, 219, 172-177.	2.0	29
243	Chronic obstructive pulmonary disease associated with increased risk of bipolar disorder. Chronic Respiratory Disease, 2017, 14, 151-160.	1.0	13
244	Bipolar Disorder and the Vascular System: Mechanisms and New Prevention Opportunities. Canadian Journal of Cardiology, 2017, 33, 1565-1576.	0.8	53
245	Anti-inflammatory treatments for mood disorders: Systematic review and meta-analysis. Journal of Psychopharmacology, 2017, 31, 1137-1148.	2.0	97
246	Correlation between alterations of inflammatory markers and treatment with atypical antipsychotics in patients diagnosed with bipolar affective disorder. European Psychiatry, 2017, 41, S422-S422.	0.1	2
247	Serum TNF-related weak inducer of apoptosis (TWEAK) and TNF-related apoptosis-inducing ligand (TRAIL) levels of patients with bipolar disorder in manic episode, in remission and healthy controls. Psychiatry Research, 2017, 257, 338-345.	1.7	6
248	Sleep and Cardiovascular Dysfunctions in Bipolar Disorder. Current Sleep Medicine Reports, 2017, 3, 251-261.	0.7	1
249	Serious mental illness and medical comorbidities: Findings from an integrated health care system. Journal of Psychosomatic Research, 2017, 100, 35-45.	1.2	64
250	Bipolar disorder moderates associations between linoleic acid and markers of inflammation. Journal of Psychiatric Research, 2017, 85, 29-36.	1.5	6
251	Pathogen–Host Defense in the Evolution of Depression: Insights into Epidemiology, Genetics, Bioregional Differences and Female Preponderance. Neuropsychopharmacology, 2017, 42, 5-27.	2.8	48
252	Bipolar Spectrum Disorders in Male Youth: The Interplay between Symptom Severity, Inflammation, Steroid Secretion, and Body Composition. Frontiers in Psychiatry, 2017, 8, 207.	1.3	7
253	Is Toxoplasma gondii a Trigger of Bipolar Disorder?. Pathogens, 2017, 6, 3.	1.2	60
254	White Matter Tract Integrity in Alzheimer's Disease vs. Late Onset Bipolar Disorder and Its Correlation with Systemic Inflammation and Oxidative Stress Biomarkers. Frontiers in Aging Neuroscience, 2017, 9, 179.	1.7	16
255	Physical Activity Modulates Common Neuroplasticity Substrates in Major Depressive and Bipolar Disorder. Neural Plasticity, 2017, 2017, 1-37.	1.0	33
256	Animal models for bipolar disorder: from bedside to the cage. International Journal of Bipolar Disorders, 2017, 5, 35.	0.8	55
257	Neuroimmune Biomarkers in Mental Illness. Current Topics in Behavioral Neurosciences, 2018, 40, 45-78.	0.8	27

#	Article	IF	CITATIONS
258	A pilot study of minocycline for the treatment of bipolar depression: Effects on cortical glutathione and oxidative stress in vivo. Journal of Affective Disorders, 2018, 230, 56-64.	2.0	36
259	Elevation of plasma neutrophil gelatinase-associated lipocalin (NGAL) levels in schizophrenia patients. Journal of Affective Disorders, 2018, 226, 307-312.	2.0	18
260	Systemic autoimmune diseases are associated with an increased risk of bipolar disorder: A nationwide population-based cohort study. Journal of Affective Disorders, 2018, 227, 31-37.	2.0	36
261	Proinflammatory Cytokines, Mood, and Sleep in Interepisode Bipolar Disorder and Insomnia: A Pilot Study With Implications for Psychosocial Interventions. Psychosomatic Medicine, 2018, 80, 87-94.	1.3	14
262	Total sleep time and kynurenine metabolism associated with mood symptom severity in bipolar disorder. Bipolar Disorders, 2018, 20, 27-34.	1.1	37
263	Patients with Hidradenitis Suppurativa Have a High Psychiatric Disease Burden: AÂFinnish Nationwide Registry Study. Journal of Investigative Dermatology, 2018, 138, 46-51.	0.3	63
264	ALDH2 modulated changes in cytokine levels and cognitive function in bipolar disorder: A 12-week follow-up study. Australian and New Zealand Journal of Psychiatry, 2018, 52, 680-689.	1.3	2
265	No evidence for airborne transmission of Toxoplasma gondii in a very high prevalence area in Lancaster County. Pteridines, 2018, 29, 172-178.	0.5	1
266	Periodontal, metabolic, and cardiovascular disease: Exploring the role of inflammation and mental health. Pteridines, 2018, 29, 124-163.	0.5	36
267	In the Realm of Psychoneuroimmunology: The Role of Celecoxib as an Add-On Treatment for Bipolar Mania. Molecular Neuropsychiatry, 2018, 4, 164-167.	3.0	2
268	Treatment-Refractory Mania with Psychosis in a Post-Transplant Patient on Tacrolimus: A Case Report. Clinical Medicine and Research, 2018, 16, 47-49.	0.4	10
269	Anti-cytokine agents for anhedonia: targeting inflammation and the immune system to treat dimensional disturbances in depression. Therapeutic Advances in Psychopharmacology, 2018, 8, 337-348.	1.2	50
270	Leukocyte telomere length in patients with bipolar disorder: An updated meta-analysis and subgroup analysis by mood status. Psychiatry Research, 2018, 270, 41-49.	1.7	53
271	Le microbiote intestinal gouverne-t-il notre cerveauÂ?. Annales Medico-Psychologiques, 2018, 176, 824-830.	0.2	0
272	Emotional hyperâ€reactivity and cardiometabolic risk in remitted bipolar patients: a machine learning approach. Acta Psychiatrica Scandinavica, 2018, 138, 348-359.	2.2	19
273	Inflammation in Bipolar Disorder. , 2018, , 445-454.		3
274	Neuroimmune Impacts of Early-Life Stress on Development and Psychopathology. Current Topics in Behavioral Neurosciences, 2018, 43, 423-447.	0.8	39
275	Inflammatory responses and inflammation-associated diseases in organs. Oncotarget, 2018, 9, 7204-7218.	0.8	2,597

#	Article	IF	CITATIONS
276	Resolution of inflammation and mood disorders. Experimental and Molecular Pathology, 2018, 105, 190-201.	0.9	29
277	Cerebral blood flow in bipolar disorder: A systematic review. Journal of Affective Disorders, 2018, 241, 505-513.	2.0	55
278	Bidirectional association between gastroesophageal reflux disease and depression: Two different nested case-control studies using a national sample cohort. Scientific Reports, 2018, 8, 11748.	1.6	64
279	Food for Mood: Relevance of Nutritional Omega-3 Fatty Acids for Depression and Anxiety. Frontiers in Physiology, 2018, 9, 1047.	1.3	97
280	Coadministration of lithium and celecoxib reverses manic-like behavior and decreases oxidative stress in a dopaminergic model of mania induced in rats. Translational Psychiatry, 2019, 9, 297.	2.4	11
281	Eating disorders, bipolar disorders and other mood disorders: complex and under-researched relationships. Journal of Eating Disorders, 2019, 7, 32.	1.3	14
282	Neurobiology and Therapeutic Potential of Cyclooxygenase-2 (COX-2) Inhibitors for Inflammation in Neuropsychiatric Disorders. Frontiers in Psychiatry, 2019, 10, 605.	1.3	43
283	Rapid onset of first manic episode after bariatric surgery. Australian and New Zealand Journal of Psychiatry, 2019, 53, 701-702.	1.3	0
284	The Relationship Between Neuroimmunity and Bipolar Disorder: Mechanism and Translational Application. Neuroscience Bulletin, 2019, 35, 595-607.	1.5	19
285	Serum level of nerve growth factor is a potential biomarker of conversion to bipolar disorder in women with major depressive disorder. Psychiatry and Clinical Neurosciences, 2019, 73, 590-593.	1.0	23
286	Neuroendocrine abnormalities associated with untreated first episode patients with major depressive disorder and bipolar disorder. Psychoneuroendocrinology, 2019, 107, 119-123.	1.3	27
287	Bipolar disorder and the endocannabinoid system. Acta Neuropsychiatrica, 2019, 31, 193-201.	1.0	17
288	Add-on HD-tDCS for obsessive-compulsive disorder with comorbid bipolar affective disorder: A case series. Asian Journal of Psychiatry, 2019, 43, 87-90.	0.9	18
289	Pragmatic Trials: Solving the Dilemma of Psychiatric Nonadherence. , 2019, , 191-200.		0
290	Risk of cardiometabolic diseases among siblings of patients with bipolar disorder. Journal of Affective Disorders, 2019, 253, 171-175.	2.0	10
291	Genetic Overlap Between Alzheimer's Disease and Bipolar Disorder Implicates the MARK2 and VAC14 Genes. Frontiers in Neuroscience, 2019, 13, 220.	1.4	42
292	Similarly in depression, nuances of gut microbiota: Evidences from a shotgun metagenomics sequencing study on major depressive disorder versus bipolar disorder with current major depressive episode patients. Journal of Psychiatric Research, 2019, 113 , 90-99.	1.5	111
293	Effects of lithium on inflammatory and neurotrophic factors after an immune challenge in a lisdexamfetamine animal model of mania. Revista Brasileira De Psiquiatria, 2019, 41, 419-427.	0.9	9

#	Article	IF	CITATIONS
294	Inflammatory mediators and dual depression: Potential biomarkers in plasma of primary and substance-induced major depression in cocaine and alcohol use disorders. PLoS ONE, 2019, 14, e0213791.	1.1	18
295	Biomarkers for Drugs of Abuse and Neuropsychiatric Disorders. , 2019, , 911-928.		0
296	Elevated Familial Cardiovascular Burden Among Adolescents With Familial Bipolar Disorder. Frontiers in Psychiatry, 2019, 10, 8.	1.3	19
298	Evaluation of serum inflammatory markers in treatment-resistant manic patients and adequate responder manic patients. Psychiatry Research, 2019, 272, 73-79.	1.7	9
299	Lamotrigine as a mood stabilizer: insights from the pre-clinical evidence. Expert Opinion on Drug Discovery, 2019, 14, 179-190.	2.5	10
300	Bipolar disorder and 1513A>C P2RX7 polymorphism frequency. Neuroscience Letters, 2019, 694, 143-147.	1.0	7
301	Omega-3 PUFAs and vitamin D co-supplementation as a safe-effective therapeutic approach for core symptoms of autism spectrum disorder: case report and literature review. Nutritional Neuroscience, 2020, 23, 779-790.	1.5	21
302	Inflammation, brain structure and cognition interrelations among individuals with differential risks for bipolar disorder. Brain, Behavior, and Immunity, 2020, 83, 192-199.	2.0	11
303	<i>Pro Re Nata</i> Medication Use in Acute Care Adolescent Psychiatric Unit. Journal of Child and Adolescent Psychopharmacology, 2020, 30, 250-260.	0.7	9
304	Pediatric Acute-onset Neuropsychiatric Syndrome and Mycoplasma Pneumoniae Infection: A Case Report Analysis with a Metabolomics Approach. Current Pediatric Reviews, 2020, 16, 183-193.	0.4	15
305	Mechanisms of insulin resistance, mitochondrial dysfunction and the action of the ketogenic diet in bipolar disorder. Focus on the PI3K/AKT/HIF1-a pathway. Medical Hypotheses, 2020, 145, 110299.	0.8	22
306	Inflammation as a Mechanism of Bipolar Disorder Neuroprogression. Current Topics in Behavioral Neurosciences, 2020, 48, 215-237.	0.8	8
307	Alexithymia and metabolic syndrome: the mediating role of binge eating. Eating and Weight Disorders, 2021, 26, 1813-1823.	1.2	6
308	Mania Associated With Supratherapeutic Tacrolimus Levels in a Patient With No Psychiatric History. Psychosomatics, 2020, 61, 769-773.	2.5	5
309	Cyclooxygenase Inhibition Safety and Efficacy in Inflammation-Based Psychiatric Disorders. Molecules, 2020, 25, 5388.	1.7	15
310	Bipolar disorders. Lancet, The, 2020, 396, 1841-1856.	6.3	419
311	Cashew (Anacardium occidentale L.) Nuts Counteract Oxidative Stress and Inflammation in an Acute Experimental Model of Carrageenan-Induced Paw Edema. Antioxidants, 2020, 9, 660.	2.2	63
312	Plasma MCP-1 levels in bipolar depression during cyclooxygenase-2 inhibitor combination treatment. Journal of Psychiatric Research, 2020, 129, 189-197.	1.5	11

#	Article	IF	CITATIONS
313	Markers of Regenerative Processes in Patients with Bipolar Disorder: A Case-control Study. Brain Sciences, 2020, 10, 408.	1.1	2
314	Molecular Biological Aspects of Depressive Disorders: A Modern View. Molecular Biology, 2020, 54, 639-660.	0.4	7
315	Alterations in plasma kynurenine pathway metabolites in children and adolescents with bipolar disorder and unaffected offspring of bipolar parents: A preliminary study. Bipolar Disorders, 2020, 23, 689-696.	1.1	5
316	Intracellular Signaling Cascades in Bipolar Disorder. Current Topics in Behavioral Neurosciences, 2020, 48, 101-132.	0.8	9
317	Neuroinflammation, Pain and Depression: An Overview of the Main Findings. Frontiers in Psychology, 2020, 11, 1825.	1.1	40
318	Proinflammatory Cytokines Predict Brain Metabolite Concentrations in the Anterior Cingulate Cortex of Patients With Bipolar Disorder. Frontiers in Psychiatry, 2020, 11, 590095.	1.3	16
319	Transcriptomic Deconvolution of Dorsal Striata Reveals Increased Monocyte Fractions in Bipolar Disorder. Complex Psychiatry, 2020, 6, 83-88.	1.3	2
320	An Imaging and Blood Biomarkers Open Dataset on Alzheimer's Disease vs. Late Onset Bipolar Disorder. Frontiers in Aging Neuroscience, 2020, 12, 583212.	1.7	0
321	Call to action regarding the vascularâ€bipolar link: A report from the Vascular Task Force of the International Society for Bipolar Disorders. Bipolar Disorders, 2020, 22, 440-460.	1.1	66
322	Proteomic Profiling as a Diagnostic Biomarker for Discriminating Between Bipolar and Unipolar Depression. Frontiers in Psychiatry, 2020, 11, 189.	1.3	9
323	Dopamine activates NF-κB and primes the NLRP3 inflammasome in primary human macrophages. Brain, Behavior, & Immunity - Health, 2020, 2, 100030.	1.3	19
324	Cytokine changes in different types of depression: Specific or general?. Neurology Psychiatry and Brain Research, 2020, 36, 39-51.	2.0	6
325	Body Mass Index Predicts Decline in Executive Function in Bipolar Disorder: Preliminary Data of a 12-Month Follow-up Study. Neuropsychobiology, 2021, 80, 1-11.	0.9	8
326	Brain-derived neurotrophic factor in bipolar disorder: Associations with age at onset and illness duration. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 108, 110075.	2.5	8
327	Influence of genetic variations in IL1B on brain region volumes in bipolar patients and controls. Psychiatry Research, 2021, 296, 113606.	1.7	4
328	Cumulative Cardiovascular Disease Risk and Triglycerides Differentially Relate to Subdomains of Executive Function in Bipolar Disorder; preliminary findings. Journal of Affective Disorders, 2021, 278, 556-562.	2.0	10
329	Bipolar disorder and cardiovascular dysfunction: Mechanisms and implications., 2021,, 223-233.		0
330	Older-age bipolar disorder., 2021,, 335-345.		0

#	Article	IF	CITATIONS
331	Decreased Plasma Levels of Angiotensin-Converting Enzyme Among Patients With Bipolar Disorder. Frontiers in Neuroscience, 2021, 15, 617888.	1.4	8
332	Inflammation is correlated with abnormal functional connectivity in unmedicated bipolar depression: an independent component analysis study of resting-state fMRI. Psychological Medicine, 2022, 52, 3431-3441.	2.7	8
333	Identification of Celecoxib-Targeted Proteins Using Label-Free Thermal Proteome Profiling on Rat Hippocampus. Molecular Pharmacology, 2021, 99, 308-318.	1.0	9
334	Prefrontal dopamine D1 receptor manipulation influences anxiety behavior and induces neuroinflammation within the hippocampus. International Journal of Bipolar Disorders, 2021, 9, 9.	0.8	7
335	Obesity and overweight among children and adolescents with bipolar disorder from the general population: A review of the scientific literature and a metaâ€analysis. Microbial Biotechnology, 2022, 16, 113-125.	0.9	9
336	Anti-TNF-α Compounds as a Treatment for Depression. Molecules, 2021, 26, 2368.	1.7	42
337	Altered Neuronal Support and Inflammatory Response in Bipolar Disorder Patient-Derived Astrocytes. Stem Cell Reports, 2021, 16, 825-835.	2.3	20
338	Bipolar disorder and the risk for stroke incidence and mortality: a meta-analysis. Neurological Sciences, 2022, 43, 467-476.	0.9	7
339	Insulin Resistance and Blood-Brain Barrier Dysfunction Underlie Neuroprogression in Bipolar Disorder. Frontiers in Psychiatry, 2021, 12, 636174.	1.3	14
340	Dysregulated inflammation may predispose patients with serious mental illnesses to severe COVID‑19 (Review). Molecular Medicine Reports, 2021, 24, .	1.1	5
341	Structural neuroimaging phenotypes of a novel multi-gene risk score in youth bipolar disorder. Journal of Affective Disorders, 2021, 289, 135-143.	2.0	1
342	Actualities in immunological markers and electrochemical sensors for determination of dopamine and its metabolites in psychotic disorders (Review). Experimental and Therapeutic Medicine, 2021, 22, 888.	0.8	1
343	Association Analysis Between Interleukin 1 Beta Locus-511 Gene Polymorphism and Bipolar I Disorder: A Case-control Study in an Iranian Population. Modern Care Journal, 2021, 18, .	0.2	1
344	Aiding and Abetting Anhedonia: Impact of Inflammation on the Brain and Pharmacological Implications. Pharmacological Reviews, 2021, 73, 1084-1117.	7.1	36
345	Ketogenic diet in therapy of bipolar affective disorder - case report and literature review. Psychiatria Polska, 2022, 56, 1345-1363.	0.2	7
346	Mind-Body Connection: Cardiovascular Sequelae of Psychiatric Illness. Current Problems in Cardiology, 2022, 47, 100959.	1.1	8
347	COVIDâ€19â€related fears and information frequency predict sleep behavior in bipolar disorder. Brain and Behavior, 2021, 11, e02182.	1.0	10
348	Anti-Inflammatory Potentials of the n-Hexane Fraction of Alstonia boonei Stem Bark in Lipopolysaccharide-Induced Inflammation in Wistar Rats. Journal of Inflammation Research, 2021, Volume 14, 3905-3920.	1.6	2

#	Article	IF	CITATIONS
349	A pilot study indicating the dysregulation of the complement and coagulation cascades in treated schizophrenia and bipolar disorder patients. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2021, 1869, 140657.	1.1	13
350	Secondary Mania induced by <scp>TNF</scp> â€Î± inhibitors: A systematic review. Psychiatry and Clinical Neurosciences, 2022, 76, 15-21.	1.0	4
351	Lower pro- to anti-inflammatory ratios associated with reduced neurocognitive flexibility in symptomatic adolescents with bipolar disorder. Journal of Affective Disorders, 2021, 292, 430-438.	2.0	6
352	Elevated C-reactive protein levels across diagnoses: The first comparison among inpatients with major depressive disorder, bipolar disorder, or obsessive–compulsive disorder. Journal of Psychosomatic Research, 2021, 150, 110604.	1.2	6
353	Severe Affective and Behavioral Dysregulation in Youths Is Associated with a Proinflammatory State 1MH and LP contributed equally to the paper. Zeitschrift FÄœr Kinder- Und Jugendpsychiatrie Und Psychotherapie, 2013, 41, 393-399.	0.4	11
354	Can cycles of chills and fever resolve bipolar disorder mania?. BMJ Case Reports, 2014, 2014, bcr2013203127-bcr2013203127.	0.2	3
355	Combination of dextromethorphan and memantine in treating bipolar spectrum disorder: a 12-week double-blind randomized clinical trial. International Journal of Bipolar Disorders, 2020, 8, 11.	0.8	7
356	Is diet important in bipolar disorder?. Psychiatria Polska, 2018, 52, 783-795.	0.2	12
357	Inflammation's Association with Metabolic Profiles before and after a Twelve-Week Clinical Trial in Drug-Naìve Patients with Bipolar II Disorder. PLoS ONE, 2013, 8, e66847.	1.1	36
358	Rheumatoid Arthritis and the Risk of Bipolar Disorder: A Nationwide Population-Based Study. PLoS ONE, 2014, 9, e107512.	1.1	38
359	Coordinated Gene Expression of Neuroinflammatory and Cell Signaling Markers in Dorsolateral Prefrontal Cortex during Human Brain Development and Aging. PLoS ONE, 2014, 9, e110972.	1.1	44
360	Irritable Brain Caused by Irritable Bowel? A Nationwide Analysis for Irritable Bowel Syndrome and Risk of Bipolar Disorder. PLoS ONE, 2015, 10, e0118209.	1.1	15
361	Disturbances in Hypothalamic-Pituitary-Adrenal Axis and Immunological Activity Differentiating between Unipolar and Bipolar Depressive Episodes. PLoS ONE, 2015, 10, e0133898.	1.1	24
362	Epigenetics of Metabolic Syndrome as a Mood Disorder. Journal of Clinical Medicine Research, 2018, 10, 453-460.	0.6	7
363	Repurposed Drugs for the Treatment of Schizophrenia and Bipolar Disorders. Current Topics in Medicinal Chemistry, 2013, 13, 2364-2385.	1.0	6
364	Periodontal Pathogens and Neuropsychiatric Health. Current Topics in Medicinal Chemistry, 2020, 20, 1353-1397.	1.0	11
365	Eicosanoids Derived From Arachidonic Acid and Their Family Prostaglandins and Cyclooxygenase in Psychiatric Disorders. Current Neuropharmacology, 2015, 13, 776-785.	1.4	74
366	The Microbiota-Gut-Brain Axis in Neuropsychiatric Disorders: Pathophysiological Mechanisms and Novel Treatments. Current Neuropharmacology, 2018, 16, 559-573.	1.4	147

#	Article	IF	Citations
367	The "Entourage Effect― Terpenes Coupled with Cannabinoids for the Treatment of Mood Disorders and Anxiety Disorders. Current Neuropharmacology, 2020, 18, 87-96.	1.4	117
368	Adjunct Treatments for Schizophrenia and Bipolar Disorder: What to Try When You Are Out of Ideas. Clinical Schizophrenia and Related Psychoses, 2012, 5, 208-216C.	1.4	50
369	Inflammation in Post-Traumatic Stress Disorder (PTSD): A Review of Potential Correlates of PTSD with a Neurological Perspective. Antioxidants, 2020, 9, 107.	2.2	74
370	Cardiometabolic Health in Bipolar Disorder. Psychiatric Annals, 2012, 42, 179-183.	0.1	7
371	Are Mood and Anxiety Disorders Inflammatory Diseases?. Psychiatric Annals, 2015, 45, 240-248.	0.1	5
372	Bipolar Disorder. Journal of Clinical Psychiatry, 2010, 71, 1689-1695.	1.1	147
373	Randomized Controlled Trial to Assess Reduction of Cardiovascular Disease Risk in Patients With Bipolar Disorder. Journal of Clinical Psychiatry, 2013, 74, e655-e662.	1.1	67
374	Gender Differences, Clinical Correlates, and Longitudinal Outcome of Bipolar Disorder With Comorbid Migraine. Journal of Clinical Psychiatry, 2014, 75, 512-519.	1.1	56
375	Inflammatory Markers Among Adolescents and Young Adults With Bipolar Spectrum Disorders. Journal of Clinical Psychiatry, 2015, 76, 1556-1563.	1.1	61
376	Platelet's Fatty Acids and Differential Diagnosis of Major Depression and Bipolar Disorder through the Use of an Unsupervised Competitive-Learning Network Algorithm (SOM). Open Journal of Depression, 2014, 03, 52-73.	0.2	11
377	Effect of Increased Neutrophil-to-Lymphocyte Ratio (NLR) and Decreased Mean Platelet Volume (MPV) Values on Inflammation in Acute Mania. Noropsikiyatri Arsivi, 2016, 53, 317-320.	0.7	25
378	Evaluation of plasma cytokines in patients with cocaine use disorders in abstinence identifies transforming growth factor alpha ($TGF\hat{l}_{\pm}$) as a potential biomarker of consumption and dual diagnosis. PeerJ, 2017, 5, e3926.	0.9	23
380	Bipolare affektive Störungen. , 2015, , 1-36.		0
381	Late Onset Bipolar Disorder Versus Alzheimer Disease. Smart Innovation, Systems and Technologies, 2016, , 377-384.	0.5	O
382	Bipolare affektive Störungen. , 2017, , 1819-1854.		1
383	Complementary and Integrative Therapies for Older Age Bipolar Disorder. , 2017, , 191-212.		O
384	İnflamatuar Biyobelirteçler Açısından Bipolar Bozukluk Tip 1 Tanılı Hastaların Sağlıklı Kontroll Karşılaştırılması. Adıyaman Üniversitesi Sağlık Bilimleri Dergisi, 0, , 1452-1460.	erle 0.3	2
385	Phenytoin in Bipolar Depression: An Old Chapter, but Not Yet Properly Evaluated. , 2019, 1, .		O

#	Article	IF	CITATIONS
386	Safety and Efficacy of Combined Low-Dose Lithium and Low-Dose Aspirin: A Pharmacological and Behavioral Proof-of-Concept Study in Rats. Pharmaceutics, 2021, 13, 1827.	2.0	6
387	Affective Disorders., 2021,,.		0
389	The Role of Resilience and Age on Quality of life in Patients with Pain Disorders. Basic and Clinical Neuroscience, 2013, 4, 24-30.	0.3	16
390	Inflammation, stress, and gut-brain axis as therapeutic targets in bipolar disorder., 2022, , 403-437.		1
391	C-Reactive Protein in Bipolar Disorder and Unipolar Depression. Journal of Nervous and Mental Disease, 2022, 210, 510-514.	0.5	2
392	Elevated atherogenic lipid profile in youth with bipolar disorder during euthymia and hypomanic/mixed but not depressive states. Journal of Psychosomatic Research, 2022, 156, 110763.	1.2	1
393	Treatment-induced mood switching in affective disorders. Acta Neuropsychiatrica, 2022, 34, 55-68.	1.0	5
394	Plasma BDNF and Cytokines Correlated with Protein Biomarkers for Bipolar II Disorder. Journal of Personalized Medicine, 2021, 11, 1282.	1.1	3
401	Childhood trauma, interleukin-17, C-reactive protein, metabolism, and psychosocial functioning in bipolar depression. Journal of Affective Disorders Reports, 2022, , 100357.	0.9	1
402	Elevated C-reactive protein among symptomatic youth with bipolar disorder. Journal of Psychopharmacology, 2022, 36, 645-652.	2.0	3
405	Clinical Value of Inflammatory and Neurotrophic Biomarkers in Bipolar Disorder: A Systematic Review and Meta-Analysis. Biomedicines, 2022, 10, 1368.	1.4	4
406	Depressive-Like Behavior Accompanies Neuroinflammation in an Animal Model of Bipolar Disorder Induced by Ouabain. SSRN Electronic Journal, 0, , .	0.4	0
407	The genetics of bipolar disorder with obesity and type 2 diabetes. Journal of Affective Disorders, 2022, 313, 222-231.	2.0	6
408	Obesity and mixed features in bipolar disorder: A systematic review. Psychiatry Research Communications, 2022, 2, 100062.	0.2	1
409	Neuroimmune Crosstalk in Rheumatoid Arthritis. International Journal of Molecular Sciences, 2022, 23, 8158.	1.8	13
410	Depressive-like behavior accompanies neuroinflammation in an animal model of bipolar disorder symptoms induced by ouabain. Pharmacology Biochemistry and Behavior, 2022, 219, 173434.	1.3	4
411	Oxidative stress parameters and antioxidants in adults with unipolar or bipolar depression versus healthy controls: Systematic review and meta-analysis. Journal of Affective Disorders, 2022, 314, 211-221.	2.0	18
412	Metabolomic and proteomic profiling in bipolar disorder patients revealed potential molecular signatures related to hemostasis. Metabolomics, 2022, 18, .	1.4	4

#	Article	IF	Citations
413	A Longitudinal Study of the Association between the LEPR Polymorphism and Treatment Response in Patients with Bipolar Disorder. International Journal of Molecular Sciences, 2022, 23, 9635.	1.8	0
414	Effect of quetiapine on inflammation and immunity: a systematic review. International Journal of Psychiatry in Clinical Practice, 2023, 27, 196-207.	1.2	2
415	Sleep Disturbance and Bipolar Depression in Youth. Current Neuropharmacology, 2022, 20, .	1.4	0
416	Brain-Derived Neurotrophic Factor: A Novel Dynamically Regulated Therapeutic Modulator in Neurological Disorders. Neurochemical Research, 2023, 48, 317-339.	1.6	14
417	Dopamine, Immunity, and Disease. Pharmacological Reviews, 2023, 75, 62-158.	7.1	43
418	Recurrent Catatonia: Infection and Immunity in an Idiopathic Illness. Journal of Psychiatric Practice, 2023, 29, 82-89.	0.3	1
419	Heightened inflammation in bipolar disorder occurs independent of symptom severity and is explained by body mass index. Brain, Behavior, & Immunity - Health, 2023, 29, 100613.	1.3	5
420	The effect of adding curcumin to sodium valproate in treatment of patients with bipolar disorder in the acute phase of mania: A randomized double-blind clinical trial. Frontiers in Psychiatry, 0, 14 , .	1.3	1
421	Effects of Cannabidiol on Innate Immunity: Experimental Evidence and Clinical Relevance. International Journal of Molecular Sciences, 2023, 24, 3125.	1.8	7
422	Cortical thickness alterations are associated with astrocytes and excitatory neuron-specific transcriptome signatures in pediatric bipolar disorder. Cerebral Cortex, 0, , .	1.6	0
423	Clinical characteristics of bipolar 1 disorder in relation to interleukin-6: a cross-sectional study among Egyptian patients. Middle East Current Psychiatry, 2023, 30, .	0.5	1
424	Glial-Neuronal Interaction in Synapses: A Possible Mechanism of the Pathophysiology of Bipolar Disorder. Advances in Experimental Medicine and Biology, 2023, , 191-208.	0.8	3
425	Nerve Growth Factor in Psychiatric Disorders: A Scoping Review. Indian Journal of Psychological Medicine, 2023, 45, 555-564.	0.6	0
439	Staging Biomarkers in Psychiatry. , 2023, , 123-137.		O